Updates

Announcements

Result of WRAP Retail Offer and TVR

Mar 23, 2026

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, further to its Fundraising announcement published on 17 March 2026 at 7:00 a.m. (the “Fundraising RNS“) and the WRAP Retail Offer announcement published on 17 March 2026 at 7:01 a.m. (the “WRAP RNS“), announces the result of the WRAP Retail Offer and provide an update on…
Publication of Circular

Mar 19, 2026

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces thatfurther to its ‘Fundraising’ announcement, published on 17 March 2026 at 7:00 a.m. (the “FundraisingRNS”), a circular convening a General Meeting has today been sent to shareholders.The General Meeting is scheduled to be held at 11.00 a.m. on 7 April 2026, at the offices…
ImmuPharma to present live on ‘Investor Meet Company’ platform Friday 20 March 2026 @ 12:00 (GMT)

Mar 18, 2026

ImmuPharma PLC (LSE AIM:), the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics is pleased to announce that ImmuPharma’s Tim McCarthy, CEO, Dr Sébastien Goudreau, CSO, and Dr Tim Franklin, COO, will provide a live presentation relating to the Company’s announcement, released on Tuesday 17 March 2026, titled: P140 Update – remains on track…
WRAP Retail Offer for up to £1.5 million

Mar 17, 2026

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION…
P140 Update; Fundraise, Related Party Transaction

Mar 17, 2026

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2026 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED BY THE EUROPEAN UNION (WITHDRAWAL) ACT 2020 (UK MAR). ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS…
TR-1: Standard form for notification of major holdings

Jan 6, 2026

TR-1: Standard form for notification of major holdings from Luca & Associates AG To download form Click here
IMMUPHARMA ATTENDING JP MORGAN CONFERENCE & BIOTECH SHOWCASE™

Jan 6, 2026

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO, will be attending both the JP Morgan Conference and the Biotech Showcase from 12-14 January 2026, in San Francisco, USA. The JP Morgan conference and Biotech Showcase are annual premier partnering events,…
Corporate Update

Nov 24, 2025

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces an update on P140 partnership discussions. In the Corporate Update notification of 23 October 2025, ImmuPharma advised that it had started to engage with a number of potential partners on P140, and that the Company’s stated objective was to complete a deal by the…
TR1 from Lanstead – Major interest in shares

Nov 4, 2025

TR-1: Standard form for notification of major holdings from Lanstead To download form Click here
IMMUPHARMA ATTENDING BIO-EUROPE

Oct 27, 2025

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO will be attending the forthcoming Bio-Europe Conference in Vienna, from 3-5 November 2025. BIO-Europe Vienna 2025, is the 31st annual premier biopharma partnering event. It brings together over 5,700 life science…
Launch of New Website & Corporate Update

Oct 23, 2025

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the launch of its new corporate website, marking another step in the Company’s scientific and corporate evolution and placing its proprietary P140 autoimmune platform at the forefront of its strategy. Website Showcase | P140 Platform – Scientific Advancement and Mechanism of…
Appointment of Independent Non-Executive Director

Oct 13, 2025

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the appointment of Ketan Patel to the Board, as an independent Non-Executive Director. The appointment is with immediate effect. Ketan is an experienced investment professional and brings extensive expertise in financial markets with a focus in the UK healthcare and life science sectors. He has been a long-term…
TR1 from Luca & Associates AG – Major interest in shares

Oct 7, 2025

TR-1: Standard form for notification of major holdings from Luca & Associates AG To download form Click here
Exercise of Warrants; Total Voting Rights

Sep 17, 2025

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that the Company has received notice of exercise of 500,000 warrants over New Ordinary Shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £25,000. New Ordinary Shares and Admission The New Ordinary Shares have been…
Exercise of Warrants; Total Voting Rights

Sep 11, 2025

ImmuPharma plc (LSE : IMM), the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announces that the Company has received notice of exercise of 2,500,000 warrants over New Ordinary Shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £125,000. The New Ordinary Shares have been allotted today and…
Appointments of Chief Scientific Officer and Head of R&D

Sep 1, 2025

ImmuPharma PLC (LSE: IMM), a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announces key appointments, in conjunction with the filing of a groundbreaking new patent application for its lead asset P140, separately announced today. Recognising the significance of this major step forward, Dr Sébastien Goudreau has been promoted into the position of Chief…
ImmuPharma Files Groundbreaking New Patent Application for P140: First-in-Class ‘Immunormalizer’ for Precision Diagnosis and Treatment of Autoimmune Diseases

Sep 1, 2025

ImmuPharma PLC (LSE: IMM), a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, today announces the filing of a groundbreaking new patent application for its lead asset P140, the world’s first “Immunormalizer.” The patent application which provides the potential for 20 years of commercial exclusivity, discloses a novel diagnostic test and precision treatment approach,…
TR1 from Lanstead Capital – Major interest in shares

Aug 20, 2025

Standard form for notification of major holdings To view click here
INTERIM RESULTS for the six months ended 30 June 2025

Aug 6, 2025

ImmuPharma PLC (LSE:IMM), (“ImmuPharma”, the Group or the “Company”), the specialist drug discovery and development company, is pleased to announce its unaudited interim results for the six months ended 30 June 2025 (the “Period”). Key Highlights (including post Period review) Financials For the period ended 30 June 2025, the Group reported a loss of £1.8…
2025 Result of Annual General Meeting

Jun 12, 2025

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that five of the six resolutions (Resolutions 1 – 5 inclusive) were duly passed by shareholders, while the special resolution (which required approval of 75% of votes cast to pass), was not approved. Details…
TR1 from Lanstead – Major interest in shares

May 28, 2025

TR-1: Standard form for notification of major holdings from Lanstead To download form Click here

2025 (24)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

A prodrug is a pharmacologically inactive or much less active compound that is converted inside the body (usually by metabolic enzymes) into the active drug that actually produces the therapeutic effect.

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MD, LLM

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 38 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr. Mauran-Ambrosino obtained her PhD in Chemistry from the Université de Bordeaux as a CIFRE fellow under the co-supervision of Dr. Goudreau. She then conducted postdoctoral research in cell biology at the Centre Hospitalier Universitaire (CHU) Pellegrin in Bordeaux.

In 2018, she joined Ureka, where she established both the Biology and Analytical Chemistry departments. In 2021, she became Chief Scientific Officer of Ureka Pharma. Since 2025, Dr. Mauran-Ambrosino has served as Head of R&D of the ImmuPharma Group.

Dr. Mauran-Ambrosino was a key contributor to the development of several programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr. Sébastien Goudreau obtained his PhD in Chemistry from the Université de Montréal as an NSERC fellow before conducting postdoctoral research at ETH Zürich as an FRQNT fellow. He later returned to Canada, where he co-founded FindMolecule Inc. and worked in the pharmaceutical industry.

Dr. Goudreau joined ImmuPharma in 2014 as Research Director and established the Ureka research laboratories in Bordeaux. Following the merger of ELRO and Ureka in 2019, he became Chief Scientific Officer of Ureka Pharma. In 2021, he was appointed Chief Executive Officer of ImmuPharma Biotech, and since 2025 he has served as Chief Scientific Officer of the ImmuPharma Group.

Dr. Goudreau and his team are credited with the discovery and development of several innovative programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

Announcements

Result of WRAP Retail Offer and TVR

Publication of Circular

ImmuPharma to present live on ‘Investor Meet Company’ platform Friday 20 March 2026 @ 12:00 (GMT)

WRAP Retail Offer for up to £1.5 million

P140 Update; Fundraise, Related Party Transaction

TR-1: Standard form for notification of major holdings

IMMUPHARMA ATTENDING JP MORGAN CONFERENCE & BIOTECH SHOWCASE™

Corporate Update

TR1 from Lanstead – Major interest in shares

IMMUPHARMA ATTENDING BIO-EUROPE

Launch of New Website & Corporate Update

Appointment of Independent Non-Executive Director

TR1 from Luca & Associates AG – Major interest in shares

Exercise of Warrants; Total Voting Rights

Exercise of Warrants; Total Voting Rights

Appointments of Chief Scientific Officer and Head of R&D

ImmuPharma Files Groundbreaking New Patent Application for P140: First-in-Class ‘Immunormalizer’ for Precision Diagnosis and Treatment of Autoimmune Diseases

TR1 from Lanstead Capital – Major interest in shares

INTERIM RESULTS for the six months ended 30 June 2025

2025 Result of Annual General Meeting